LncRNA UCA1 in anti-cancer drug resistance
Metrics: PDF 2746 views | HTML 4069 views | ?
Haohao Wang1,2, Zhonghai Guan1, Kuifeng He1,2, Jiong Qian1, Jiang Cao3 and Lisong Teng1,2
1Cancer Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China
2Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou, Zhejiang, P.R. China
3Clinical Research Center, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China
Lisong Teng, email: [email protected]
Keywords: long non-coding RNA, UCA1, chemoresistance, cancer
Received: February 28, 2017 Accepted: May 22, 2017 Published: June 02, 2017
The pivotal role of the long non-coding RNA (lncRNA) urothelial carcinoma associated 1 (UCA1) in anti-cancer drug resistance has been confirmed in many cancers. Overexpression of lncRNA UCA1 correlates with resistance to chemotherapeutics such as cisplatin, gemcitabine, 5-FU, tamoxifen, imatinib and EGFR-TKIs, whereas lncRNA UCA1 knockdown restores drug sensitivity. These studies highlight the potential of lncRNA UCA1 as a diagnostic and prognostic biomarker, and a therapeutic target in malignant tumors. In this review, we address the role of lncRNA UCA1 in anti-cancer drug resistance and discuss its potential in future clinical applications.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.